Why Is Cancer Focused Galera Therapeutics Stock Sinking Today?
Galera Therapeutics Inc (NASDAQ: GRTX) received official meeting minutes from the Type A meeting with the FDA held last month.
PharmaCyte Biotech Provides Corporate Update On Cell-In-A-Box Technology
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunitiesPharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company")
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter For Its Pediatric Selective Cytopheretic Device
Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its strategic partner, SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar
Mersana Therapeutics Announces FDA Has Lifted Clinical Hold On Phase 1 Clinical Trial Of XMT-2056
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Biora Therapeutics Submits Updated IND Application For BT-600; Update Includes Supplemental Information And Provides Additional Time To Complete Regulatory Review; Biora Anticipates Remaining On Track With Its Phase 1 Clinical Trial Execution Timeline
Update includes supplemental information and provides additional time to complete regulatory review Biora anticipates remaining on track with its phase 1 clinical trial execution timeline Biora Therapeutics,
LianBio Announces Topline Results From Phase 3 LIBRA Trial Of TP-03 In Chinese Patients With Demodex Blepharitis; The Co-primary Endpoints Of The LIBRA Trial Were Mite Eradication And Complete Collarette Cure At Day 43
LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial
Sarepta Says Statistically Significant Results On All Key Pre-specified Secondary Endpoints Demonstrated Evidence Of Clinically Meaningful Treatment Benefit
– Results support submission of an efficacy supplement to the BLA; US FDA has indicated openness to reviewing the data for label expansion based on the totality of evidence from EMBARK– In EMBARK, participants
Risk of Eye Infection – FDA Issues Strong Warning on Eye Drops from Major Retailers
On Friday, the FDA issued a warning to consumers, cautioning them against the use of certain over-the-coun
4DMT Gains Alignment With FDA On Plan To Lift Clinical Hold On Phase 1/2 INGLAXA Clinical Trial For 4D-310 For Fabry Disease Cardiomyopathy
Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of atypical hemolytic uremic
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a